CN100502880C - 一种三七二醇皂苷组合物及其制备方法和用途 - Google Patents
一种三七二醇皂苷组合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN100502880C CN100502880C CNB2004100906050A CN200410090605A CN100502880C CN 100502880 C CN100502880 C CN 100502880C CN B2004100906050 A CNB2004100906050 A CN B2004100906050A CN 200410090605 A CN200410090605 A CN 200410090605A CN 100502880 C CN100502880 C CN 100502880C
- Authority
- CN
- China
- Prior art keywords
- notoginseng
- ethanol
- glycol
- saponin composition
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000180649 Panax notoginseng Species 0.000 title claims abstract description 98
- 235000003143 Panax notoginseng Nutrition 0.000 title claims abstract description 98
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 21
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 12
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 claims abstract description 7
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 claims abstract description 7
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 claims abstract description 7
- 230000000552 rheumatic effect Effects 0.000 claims abstract description 7
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 128
- 239000000843 powder Substances 0.000 claims description 30
- 239000011347 resin Substances 0.000 claims description 18
- 229920005989 resin Polymers 0.000 claims description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 14
- 239000003480 eluent Substances 0.000 claims description 14
- 239000000741 silica gel Substances 0.000 claims description 14
- 229910002027 silica gel Inorganic materials 0.000 claims description 14
- 229960001866 silicon dioxide Drugs 0.000 claims description 14
- 229930182494 ginsenoside Natural products 0.000 claims description 13
- 229940089161 ginsenoside Drugs 0.000 claims description 13
- 238000005325 percolation Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 208000025747 Rheumatic disease Diseases 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- 239000000469 ethanolic extract Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000007654 immersion Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000002481 ethanol extraction Methods 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 abstract description 4
- 201000003068 rheumatic fever Diseases 0.000 abstract description 3
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 2
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 abstract 3
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 abstract 3
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 abstract 3
- 230000001741 anti-phlogistic effect Effects 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000012264 purified product Substances 0.000 abstract 1
- 239000012567 medical material Substances 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 206010042674 Swelling Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 5
- 229960000905 indomethacin Drugs 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 238000001291 vacuum drying Methods 0.000 description 5
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 4
- 230000001760 anti-analgesic effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000002917 insecticide Substances 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 235000002791 Panax Nutrition 0.000 description 2
- 241000208343 Panax Species 0.000 description 2
- 244000131316 Panax pseudoginseng Species 0.000 description 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- -1 diol saponins Chemical class 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 2
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical group 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 240000000920 Typhonium flagelliforme Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Abstract
Description
实施例编号 | 所用三七药材重量 | 浸泡、渗漉用乙醇的浓度和用量 | 采用树脂、两次洗脱树脂用乙醇的浓度和用量 | PDS的重量和主要组分的含量 |
实施例2 | 3kg | 浸泡用乙醇浓度为60wt%,用量为2倍药材重量渗漉用乙醇浓度为60wt%,用量为9倍药材重量 | D101(购自天津农药厂)第一次洗脱用乙醇的浓度为40wt%,用量为9倍药材重量第二次洗脱用乙醇的浓度为60wt%,用量为9倍药材重量 | PDS的重量:0.0945kgRb<sub>1</sub>:59.86wt%Rd:14.90wt% |
实施例3 | 3kg | 浸泡用乙醇浓度为60wt%,用量为2倍药材重量渗漉用乙醇浓度为60wt%,用量为9倍药材重量 | D101(购自天津农药厂)第一次洗脱用乙醇的浓度为40wt%,用量为9倍药材重量第二次洗脱用乙醇的浓度为60wt%,用量为8倍药材重量 | PDS的重量:0.0885kgRb<sub>1</sub>:60.18wt%Rd:13.49wt% |
实施例4 | 0.1kg | 浸泡用乙醇浓度为60wt%,用量为2倍药材重量渗漉用乙醇浓度为60wt%,用量为9倍药材重量 | D101(购自天津农药厂)第一次洗脱用乙醇的浓度为40wt%,用量为9倍药材重量第二次洗脱用乙醇的浓度为70wt%,用量为7倍药材重量 | PDS的重量:0.0039kgRb<sub>1</sub>:51.78wt%Rd:12.15wt% |
实施例5 | 0.1kg | 浸泡用乙醇浓度为60wt%,用量为2倍药材重量渗漉用乙醇浓度为60wt%,用量为9倍药材重量 | D101(购自天津农药厂)第一次洗脱用乙醇的浓度为40wt%,用量为9倍药材重量第二次洗脱用乙醇的浓度为60wt%,用量为9倍药材重量 | PDS的重量:0.004kgRb<sub>1</sub>:51.70wt%Rd:13.05wt%% |
Claims (16)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100906050A CN100502880C (zh) | 2004-11-09 | 2004-11-09 | 一种三七二醇皂苷组合物及其制备方法和用途 |
PCT/CN2004/001562 WO2006050642A1 (fr) | 2004-11-09 | 2004-12-29 | Composition contenant des saponines de panaxadiol, sa preparation et son application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100906050A CN100502880C (zh) | 2004-11-09 | 2004-11-09 | 一种三七二醇皂苷组合物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1771977A CN1771977A (zh) | 2006-05-17 |
CN100502880C true CN100502880C (zh) | 2009-06-24 |
Family
ID=36336196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100906050A Active CN100502880C (zh) | 2004-11-09 | 2004-11-09 | 一种三七二醇皂苷组合物及其制备方法和用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN100502880C (zh) |
WO (1) | WO2006050642A1 (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1869059B (zh) * | 2006-06-21 | 2012-04-18 | 海南亚洲制药有限公司 | 从人参叶中制备人参皂苷单体的方法 |
CN1869058B (zh) * | 2006-06-21 | 2012-01-11 | 海南亚洲制药有限公司 | 从三七中制备三醇组人参皂苷和二醇组人参皂苷的方法 |
CN1869057B (zh) * | 2006-06-21 | 2012-03-07 | 海南亚洲制药有限公司 | 一种三醇组人参皂苷和二醇组人参皂苷的制备方法 |
CN101007035B (zh) * | 2007-01-25 | 2010-12-01 | 上海中药创新研究中心 | 三七二醇皂苷在制备治疗记忆力减退药物中的应用 |
CN101390871B (zh) * | 2007-09-18 | 2012-01-18 | 北京本草天源药物研究院 | 含有杂质人参皂苷Rd的人参皂苷Rb1 |
JP2010155787A (ja) * | 2008-12-26 | 2010-07-15 | Maruzen Pharmaceut Co Ltd | 抗炎症剤、抗老化剤、抗肥満剤、及び育毛剤、並びに、化粧料、及び美容用飲食品 |
CN101766640B (zh) * | 2008-12-29 | 2013-04-17 | 兰州大学 | 人参皂苷-Rd丙二醇水溶液制备及其在制备抗炎、免疫抑制与抗器官移植排斥药物的新用途 |
CN104173358B (zh) * | 2014-08-27 | 2017-01-11 | 哈尔滨珍宝制药有限公司 | 一种治疗心脑血管疾病的药物组合物 |
CN105998042A (zh) * | 2016-06-02 | 2016-10-12 | 上海中医药大学附属龙华医院 | 三七总皂苷提取物在促进***生成中的用途 |
CN117414370A (zh) * | 2023-06-26 | 2024-01-19 | 云南与诺生物工程有限责任公司 | 组合物在制备用于缓解疼痛的药物中的应用 |
-
2004
- 2004-11-09 CN CNB2004100906050A patent/CN100502880C/zh active Active
- 2004-12-29 WO PCT/CN2004/001562 patent/WO2006050642A1/zh active Application Filing
Non-Patent Citations (4)
Title |
---|
RP-HPLC梯度洗脱法同时测定三七总皂苷及血塞通注射液中3种皂苷的含量. 王梅等.药物分析杂志,第20卷第6期. 2000 |
RP-HPLC梯度洗脱法同时测定三七总皂苷及血塞通注射液中3种皂苷的含量. 王梅等.药物分析杂志,第20卷第6期. 2000 * |
高效液相色谱法测定三七中人参皂苷Rd的含量. 严华等.药物分析杂志,第22卷第5期. 2002 |
高效液相色谱法测定三七中人参皂苷Rd的含量. 严华等.药物分析杂志,第22卷第5期. 2002 * |
Also Published As
Publication number | Publication date |
---|---|
CN1771977A (zh) | 2006-05-17 |
WO2006050642A1 (fr) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101214270B (zh) | 刺五加有效部位的提取物、其制备方法、其应用 | |
CN101711805A (zh) | 一种治疗类风湿性关节炎的药物组合物及其制剂 | |
CN100502880C (zh) | 一种三七二醇皂苷组合物及其制备方法和用途 | |
CN103386022B (zh) | 一种治疗结核性胸膜炎的中药组合物 | |
CN102119964A (zh) | 一种预防和治疗冠心病心绞痛的提取物,它们的制备方法及用途 | |
CN100534508C (zh) | 一种制备菝葜有效部位群的方法 | |
CN102078443B (zh) | 一种药物组合物及其用途和制剂 | |
CN102100825A (zh) | 治疗疼痛的中药组合物及其制备方法 | |
CN1771978B (zh) | 一种三七三醇皂苷组合物及其制备方法和用途 | |
CN103721148B (zh) | 一种治疗急慢性胃肠炎的益智仁组合物及其制备方法 | |
CN1820780A (zh) | 妇炎康提取物的制备方法 | |
CN101757391B (zh) | 一种治疗心血管疾病的药物组合物及其制备方法和用途 | |
CN103316074B (zh) | 一种花锚提取物、黄芪提取物与甘草提取物的组合药物及其制剂、应用 | |
CN101322734B (zh) | 具有抗炎免疫作用的轮叶党参总皂苷及其制备方法 | |
CN101642492B (zh) | 治疗慢性***的药物及其制备方法 | |
CN107629106A (zh) | 一种从三七中提取三七皂苷的方法 | |
CN101721450B (zh) | 一种用于治疗腹膜炎的苍耳根氯仿提取物的应用 | |
CN1068782C (zh) | 以栾树提取物为有效组分的抗癌药物及制备方法 | |
CN104547026A (zh) | 一种丹参叶三七提取物的制备方法及其应用 | |
CN113197947B (zh) | 一种通经活络疏通血管的组合物及其制备方法 | |
CN101461842B (zh) | 夏枯草抗肿瘤有效部位的提取方法及其提取物在制备抗肿瘤药物方面的应用 | |
CN100588411C (zh) | 含挂金灯甾类化合物的药物组合物 | |
CN101926848A (zh) | 一种治疗心脑血管病的药物组合物及其制剂 | |
CN101450133A (zh) | 一种治疗腹盆腔疾病手术后粘连的药物及其制备方法和用途 | |
CN1843407A (zh) | 一种复方中药有效部位的滴丸及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Chengdu Chinese Medicine University Huasun Pharmaceutical Co., Ltd. Assignor: Pharmaceutical Factory, Chengdu Huashen Group Corp., Ltd. Contract record no.: 2011510000214 Denomination of invention: Notoginseng glycol-saponin composition and its prepn and use Granted publication date: 20090624 License type: Exclusive License Open date: 20060517 Record date: 20110826 |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 610000 Sichuan city of Chengdu Province Southwest Economic Development Zone Jinhua Road two No. 3 Patentee after: Chengdu Taihe health technology group Limited by Share Ltd Huashen pharmaceutical factory Address before: 610000 Sichuan city of Chengdu Province Southwest Economic Development Zone Jinhua Road two No. 3 Patentee before: Pharmaceutical Factory, Chengdu Huashen Group Corp., Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20180508 Address after: 611731 B301-B310 room 3, 1168 Shu Xin Road, Chengdu high tech Zone, Sichuan. Patentee after: Chengdu Chinese Medicine University Huasun Pharmaceutical Co., Ltd. Address before: 610000 No. 3, two Jinhua Road, southwest aviation Economic Development Zone, Chengdu, Sichuan Patentee before: Chengdu Taihe health technology group Limited by Share Ltd Huashen pharmaceutical factory |
|
TR01 | Transfer of patent right | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 610000 room b301-b311, 3rd floor, No. 1168 Shuxin Avenue, hi tech Zone, Chengdu, Sichuan Patentee after: Chengdu dahuashen Pharmaceutical Co.,Ltd. Address before: 611731 B301-B310 room 3, 1168 Shu Xin Road, Chengdu high tech Zone, Sichuan. Patentee before: CHENGDU UNIVERSITY OF TCM HUASUN PHARMACEUTICAL Co.,Ltd. |